Medicare 2026: Rising Costs and Fewer Plan Options Challenge Beneficiaries
Medicare beneficiaries face higher Part B premiums, fewer Part D plans, and Medicare Advantage cancellations in 2026, making open enrollment critical for coverage decisions.
Medicare beneficiaries face higher Part B premiums, fewer Part D plans, and Medicare Advantage cancellations in 2026, making open enrollment critical for coverage decisions.
In 2025, Medicare Advantage insurers faced rising medical costs, regulatory challenges, and increased AI integration, leading to strategic service adjustments and market exits.
Learn about key changes to Medicare in 2026 including rising Part B premiums, fewer Part D plans, and the impact of Medicare Advantage plan cancellations on beneficiaries. Understand market trends and enrollment advice.
As the December 7 Medicare open enrollment deadline approaches, Medicare Advantage plans face market disruptions causing confusion and potential coverage gaps for beneficiaries in 2026.
CMS released 2027 proposed Medicare Advantage rules focusing on simplifying Star Ratings, expanding risk adjustment data use, and streamlining reporting requirements.
CMS releases the Calendar Year 2026 OPPS-ASC Final Rule, impacting Medicare reimbursement rates for hospital outpatient services, radiopharmaceuticals, and 340B drug pricing.
The Supreme Court examines presidential authority under IEEPA to impose tariffs amid debate on their fiscal impact on Social Security, Medicare, and national debt. Economic analysis highlights limited revenue benefits and significant economic drawbacks.
Explore critical enforcement trends and compliance strategies addressing cyber threats and AI integration in the legal sector, relevant for insurance and legal professionals.
Skilled nursing facilities increasingly adopt value-based care models like ACOs and Medicare Advantage SNPs to enhance patient outcomes, improve operational efficiency, and boost financial stability under evolving CMS regulations.
Hospitals challenge HHS's 340B pilot shifting drug discounts to a rebate system, citing financial risks and regulatory concerns.